The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Analysts estimate that BioNTech will report an earnings per share (EPS) of $-1.31. The market awaits BioNTech's announcement, ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

The biotechnology company on Friday said the U.K. Court of Appeal upheld the validity of its EP'949 patent. It noted the decision affirms the court's initial ruling from July 2024 that the patent is ...

COVID-19 activity is rising in much of the country. Data released Friday by federal health officials shows overall ...

BioNTech’s partner Pfizer ranked 8th last year with $41.9 billion in 2020 revenue. Meanwhile, Pfizer recently raised its 2021 COVID-19 vaccine revenue guidance to $33.5 billion, so it should ...

BioNTech is pumping 1.4 billion euros to 1.5 billion euros into research and development this year as it invests in its broader mission, which includes creating breakthrough cancer meds.

Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines. Moderna and Pfizer's vaccines have ...

BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...